EA201690354A1 - Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом - Google Patents

Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом

Info

Publication number
EA201690354A1
EA201690354A1 EA201690354A EA201690354A EA201690354A1 EA 201690354 A1 EA201690354 A1 EA 201690354A1 EA 201690354 A EA201690354 A EA 201690354A EA 201690354 A EA201690354 A EA 201690354A EA 201690354 A1 EA201690354 A1 EA 201690354A1
Authority
EA
Eurasian Patent Office
Prior art keywords
subject
expression
immunohlobulins
proteas
inhibitor
Prior art date
Application number
EA201690354A
Other languages
English (en)
Other versions
EA038246B1 (ru
Inventor
Брайан Тач
Джеремиа Дегенхардт
Андреа Лер
Кевин Квей
Кристофер Дж. Кирк
Original Assignee
Оникс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оникс Терапьютикс, Инк. filed Critical Оникс Терапьютикс, Инк.
Publication of EA201690354A1 publication Critical patent/EA201690354A1/ru
Publication of EA038246B1 publication Critical patent/EA038246B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

В документе предоставлены способы лечения опухоли у субъекта и способы определения схемы лечения для субъекта с опухолью. В образцовых аспектах способы включают измерение уровня экспрессии иммуноглобулина, FCGR2B, гена, перечисленного в табл. 4, или их сочетания. В образцовых аспектах субъект представляет собой субъекта, у которого получали образец, где в образце измеряли уровень иммуноглобулина, FCGR2B, гена, перечисленного в табл. 4, или их сочетания. Кроме того, предоставлены связанные наборы, машиночитаемые запоминающие среды, системы и способы, реализуемые процессором в компьютере.
EA201690354A 2013-08-08 2014-08-08 Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом EA038246B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361863809P 2013-08-08 2013-08-08
US201361875954P 2013-09-10 2013-09-10
US201462005904P 2014-05-30 2014-05-30
PCT/US2014/050333 WO2015021376A1 (en) 2013-08-08 2014-08-08 Immunoglobulin expression levels as biomarker for proteasome inhibitor response

Publications (2)

Publication Number Publication Date
EA201690354A1 true EA201690354A1 (ru) 2016-07-29
EA038246B1 EA038246B1 (ru) 2021-07-29

Family

ID=51358145

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690354A EA038246B1 (ru) 2013-08-08 2014-08-08 Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом

Country Status (4)

Country Link
US (4) US10870889B2 (ru)
EP (1) EP3030251B1 (ru)
EA (1) EA038246B1 (ru)
WO (1) WO2015021376A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081897A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
CN110045100B (zh) * 2019-04-01 2022-03-04 四川大学华西医院 一种慢性阻塞性肺疾病分型试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US8278038B2 (en) * 2005-06-08 2012-10-02 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2007098065A2 (en) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
EP2382329A4 (en) * 2009-01-02 2012-11-28 Univ Arkansas USES OF BORTÉZOMIB TO PREDICT THE SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA
WO2010129964A1 (en) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Drug targets for prevention of arrhythmia in heart disease
EP2661506A4 (en) 2011-01-06 2014-11-19 Univ Illinois SCN5A SPLICE VARIANTS FOR USE IN CARDIAC SUDDEN DEATH METHODS AND NEED FOR IMPLANTATION OF CARDIAC DEFIBRILLATORS
WO2012097255A2 (en) * 2011-01-14 2012-07-19 Scott & White Healthcare Therapeutic effect of heat shock proteins in preventing amylin aggregation in type 2 diabetes mellitus
CN104039328B (zh) * 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
US20160008382A1 (en) * 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer

Also Published As

Publication number Publication date
EP3030251A1 (en) 2016-06-15
US20210238691A1 (en) 2021-08-05
EA038246B1 (ru) 2021-07-29
US20160177402A1 (en) 2016-06-23
US20200354793A1 (en) 2020-11-12
US10870889B2 (en) 2020-12-22
US20230235406A1 (en) 2023-07-27
WO2015021376A1 (en) 2015-02-12
EP3030251B1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
EA201890512A1 (ru) Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
EA202090290A1 (ru) ПРИМЕНЕНИЕ БЕЛКА Cas, СПОСОБ ДЛЯ ОБНАРУЖЕНИЯ ЦЕЛЕВОЙ МОЛЕКУЛЫ НУКЛЕИНОВОЙ КИСЛОТЫ И НАБОР
EA201991105A1 (ru) Методы оценки риска с использованием общей и специфической неклеточной днк
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
BR112018002848A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
MY195999A (en) Molecular Detection/Diagnosis Reagent for Tumor
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
MX2020006151A (es) Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
BR112014000965B8 (pt) Método, aparelho e meio de armazenamento não transitório
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
WO2015048793A3 (en) Nucleic acid biomarker and use thereof
BR112014026440A2 (pt) assays, methods and apparatus for assessing rna disruption
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
EA201401201A1 (ru) Способ
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
BR112014013562A8 (pt) método, instruções de armazenamento por meio de armazenamento não transitório, e aparelho

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM